Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Atopic dermatitis is an inflammatory, chronically relapsing, highly pruritic skin disorder that has considerable impact on the quality of life. As corticosteroids are not ideal for long-term control of the disease because of their potential side effects, steroid-free topical immunomodulators have recently been developed for the treatment of atopic dermatitis. Although clinical trials do not indicate an increased risk of cutaneous infection, the clinician must be careful about viral infections such as eczema herpeticum or molluscum eczema that can be observed during treatment with pimecrolimus and tacrolimus. We report molluscum contagiosum that developed on the preauricular area treated with topical pimecrolimus.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1525-1470.2007.00443.x | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!